U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 32

1.
Preclinical and pilot study of type I FLT3 tyrosine kinase inhibitor, crenolanib, with sorafenib in acute myeloid leukemia and FLT3-internal tandem duplication
Hiroto Inaba, Jolieke G van Oosterwijk, John C. Panetta, Lie Li, Daelynn R. Buelow, James S. Blachly, Sheila Shurtleff, Ching-Hon Pui, Raul C Ribeiro, Jeffrey E. Rubnitz, Stanley Pounds, Sharyn D. Baker
Clin Cancer Res. Author manuscript; available in PMC 2022 Dec 13.
Published in final edited form as: Clin Cancer Res. 2022 Jun 13; 28(12): 2536–2546. doi: 10.1158/1078-0432.CCR-21-4450
PMCID:
PMC9197875
ArticlePDF–1.1M
2.
Population Pharmacokinetics of Crenolanib in Children and Young Adults with Brain Tumors
Cora Bisbee, Olivia Campagne, Amar Gajjar, Christopher L. Tinkle, Clinton F. Stewart
Cancer Chemother Pharmacol. Author manuscript; available in PMC 2023 Apr 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2022 Apr; 89(4): 459–468. Published online 2022 Feb 25. doi: 10.1007/s00280-022-04412-8
PMCID:
PMC8957602
ArticlePDF–1.1M
3.
Pharmacological enhancement of KCC2 gene expression exerts therapeutic effects on human Rett syndrome neurons and Mecp2 mutant mice
Xin Tang, Jesse Drotar, Keji Li, Cullen D. Clairmont, Anna Sophie Brumm, Austin J. Sullins, Hao Wu, Xiaoxiao Shawn Liu, Jinhua Wang, Nathanael S. Gray, Mriganka Sur, Rudolf Jaenisch
Sci Transl Med. Author manuscript; available in PMC 2021 May 22.
Published in final edited form as: Sci Transl Med. 2019 Jul 31; 11(503): eaau0164. doi: 10.1126/scitranslmed.aau0164
PMCID:
PMC8140401
ArticlePDF–2.3M
4.
Wu-5, a novel USP10 inhibitor, enhances crenolanib-induced FLT3-ITD-positive AML cell death via inhibiting FLT3 and AMPK pathways
Miao Yu, Zhi-xiao Fang, Wei-wei Wang, Ying Zhang, Zhi-lei Bu, Meng Liu, Xin-hua Xiao, Zi-lu Zhang, Xing-ming Zhang, Yang Cao, Ying-ying Wang, Hu Lei, Han-zhang Xu, Yun-zhao Wu, Wei Liu, Ying-li Wu
Acta Pharmacol Sin. 2021 Apr; 42(4): 604–612. Published online 2020 Jul 21. doi: 10.1038/s41401-020-0455-x
PMCID:
PMC8115260
ArticlePDF–2.8M
5.
Improved Recovery from Liver Fibrosis by Crenolanib
Doreen Reichert, Louisa Adolph, Jan Philipp Köhler, Tobias Buschmann, Tom Luedde, Dieter Häussinger, Claus Kordes
Cells. 2021 Apr; 10(4): 804. Published online 2021 Apr 4. doi: 10.3390/cells10040804
PMCID:
PMC8067177
ArticlePDF–8.0M
6.
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT and FLT3 in hematologic malignancies: Mutant KIT and FLT3 response to Tyrosine Kinase Inhibitors
Ellen Weisberg, Chengcheng Meng, Abigail Case, Martin Sattler, Hong L. Tiv, Prafulla C. Gokhale, Sara Buhrlage, Xiaoxi Liu, Jing Yang, Jinhua Wang, Nathanael Gray, Richard Stone, Sophia Adamia, Patrice Dubreuil, Sebastien Letard, James D. Griffin
Br J Haematol. Author manuscript; available in PMC 2021 Feb 17.
Published in final edited form as: Br J Haematol. 2019 Nov; 187(4): 488–501. Published online 2019 Jul 15. doi: 10.1111/bjh.16092
PMCID:
PMC7887860
ArticlePDF–1.5M
7.
The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations
Trevor J. Mathias, Karthika Natarajan, Suneet Shukla, Kshama A. Doshi, Zeba N. Singh, Suresh V. Ambudkar, Maria R. Baer
Invest New Drugs. Author manuscript; available in PMC 2020 Dec 2.
Published in final edited form as: Invest New Drugs. 2015 Apr; 33(2): 300–309. Published online 2015 Jan 20. doi: 10.1007/s10637-015-0205-y
PMCID:
PMC7709138
ArticlePDF–639K
8.
The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology
Simon D. Harding, Elena Faccenda, Christopher Southan, Adam J. Pawson, Pasquale Maffia, Stephen P. H. Alexander, Anthony P. Davenport, Doriano Fabbro, Francesca Levi‐Schaffer, Michael Spedding, Jamie A. Davies
Immunology. 2020 May; 160(1): 10–23. Published online 2020 Mar 2. doi: 10.1111/imm.13175
PMCID:
PMC7160657
ArticlePDF–4.1M
9.
Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia
Ellen Weisberg, Chengcheng Meng, Abigail E. Case, Hong L. Tiv, Prafulla C. Gokhale, Sara J. Buhrlage, Jing Yang, Xiaoxi Liu, Jinhua Wang, Nathanael Gray, Sophia Adamia, Martin Sattler, Richard Stone, James D. Griffin
J Cell Mol Med. 2020 Mar; 24(5): 2968–2980. Published online 2020 Jan 22. doi: 10.1111/jcmm.14927
PMCID:
PMC7077552
ArticlePDF–942K
10.
Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of PDGFR expression
Robert H. Berndsen, Cédric Castrogiovanni, Andrea Weiss, Magdalena Rausch, Marchien G. Dallinga, Marijana Miljkovic-Licina, Ingeborg Klaassen, Patrick Meraldi, Judy R. van Beijnum, Patrycja Nowak-Sliwinska
Br J Cancer. 2019 Jul 16; 121(2): 139–149. Published online 2019 Jun 25. doi: 10.1038/s41416-019-0498-2
PMCID:
PMC6738084
ArticlePDF–3.9M
11.
Platelet-derived growth factor receptor-α is essential for cardiac fibroblast survival
Malina J. Ivey, Jill T. Kuwabara, Kara L. Riggsbee, Michelle D. Tallquist
Am J Physiol Heart Circ Physiol. 2019 Aug 1; 317(2): H330–H344. Published online 2019 May 24. doi: 10.1152/ajpheart.00054.2019
PMCID:
PMC6732481
Article
12.
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
Haijiao Zhang, Samantha Savage, Anna Reister Schultz, Daniel Bottomly, Libbey White, Erik Segerdell, Beth Wilmot, Shannon K. McWeeney, Christopher A. Eide, Tamilla Nechiporuk, Amy Carlos, Rachel Henson, Chenwei Lin, Robert Searles, Hoang Ho, Yee Ling Lam, Richard Sweat, Courtney Follit, Vinay Jain, Evan Lind, Gautam Borthakur, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Jorge Cortes, Robert Collins, Daelynn R. Buelow, Sharyn D. Baker, Brian J. Druker, Jeffrey W. Tyner
Nat Commun. 2019; 10: 244. Published online 2019 Jan 16. doi: 10.1038/s41467-018-08263-x
PMCID:
PMC6335421
ArticlePDF–2.0M
13.
Photoaffinity-engineered protein scaffold for systematically exploring native phosphotyrosine signaling complexes in tumor samples
Bizhu Chu, An He, Yeteng Tian, Wan He, Peizhong Chen, Jintao Hu, Ruilian Xu, Wenbin Zhou, Mingjie Zhang, Pengyuan Yang, Shawn S. C. Li, Ying Sun, Pengfei Li, Tony Hunter, Ruijun Tian
Proc Natl Acad Sci U S A. 2018 Sep 18; 115(38): E8863–E8872. Published online 2018 Sep 6. doi: 10.1073/pnas.1805633115
PMCID:
PMC6156637
ArticlePDF–2.4M
14.
Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene
Valentina Indio, Annalisa Astolfi, Giuseppe Tarantino, Milena Urbini, Janice Patterson, Margherita Nannini, Maristella Saponara, Lidia Gatto, Donatella Santini, Italo F. do Valle, Gastone Castellani, Daniel Remondini, Michelangelo Fiorentino, Margaret von Mehren, Giovanni Brandi, Guido Biasco, Michael C. Heinrich, Maria Abbondanza Pantaleo
Int J Mol Sci. 2018 Mar; 19(3): 732. Published online 2018 Mar 4. doi: 10.3390/ijms19030732
PMCID:
PMC5877593
ArticlePDF–2.3M
15.
The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma
O Govaere, M Petz, J Wouters, Y-P Vandewynckel, E J Scott, B Topal, F Nevens, C Verslype, Q M Anstee, H Van Vlierberghe, W Mikulits, T Roskams
Oncogene. 2017 Nov 23; 36(47): 6605–6616. Published online 2017 Aug 7. doi: 10.1038/onc.2017.260
PMCID:
PMC5702717
ArticlePDF–4.5M
16.
Survival of pancreatic cancer cells lacking KRAS function
Mandar Deepak Muzumdar, Pan-Yu Chen, Kimberly Judith Dorans, Katherine Minjee Chung, Arjun Bhutkar, Erin Hong, Elisa M. Noll, Martin R. Sprick, Andreas Trumpp, Tyler Jacks
Nat Commun. 2017; 8: 1090. Published online 2017 Oct 23. doi: 10.1038/s41467-017-00942-5
PMCID:
PMC5653666
ArticlePDF–3.9M
17.
Effects of crenolanib, a non-selective inhibitor of PDGFR, in a mouse model of transient middle cerebral artery occlusion
Jianping Wang, Xiaojie Fu, Di Zhang, Lie Yu, Zhengfang Lu, Yufeng Gao, Xianliang Liu, Jiang Man, Sijia Li, Nan Li, Menghan Wang, Xi Liu, Xuemei Chen, Weidong Zang, Qingwu Yang, Jian Wang
Neuroscience. Author manuscript; available in PMC 2018 Nov 19.
Published in final edited form as: Neuroscience. 2017 Nov 19; 364: 202–211. Published online 2017 Sep 21. doi: 10.1016/j.neuroscience.2017.09.025
PMCID:
PMC5653447
ArticlePDF–1.4M
18.
Blockade of PDGF receptors by crenolanib has therapeutic effect in patient fibroblasts and in preclinical models of systemic sclerosis
Katsunari Makino, Tomoko Makino, Lukasz Stawski, Julio C. Mantero, Robert Lafyatis, Robert Simms, Maria Trojanowska
J Invest Dermatol. Author manuscript; available in PMC 2018 Aug 1.
Published in final edited form as: J Invest Dermatol. 2017 Aug; 137(8): 1671–1681. Published online 2017 Apr 19. doi: 10.1016/j.jid.2017.03.032
PMCID:
PMC5560111
ArticlePDF–2.8M
19.
Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC)
Madhura Joglekar-Javadekar, Steven Van Laere, Michael Bourne, Manal Moalwi, Pascal Finetti, Peter B. Vermeulen, Daniel Birnbaum, Luc Y. Dirix, Naoto Ueno, Monique Carter, Justin Rains, Abhijit Ramachandran, Francois Bertucci, Kenneth L. van Golen
Neoplasia. 2017 Jul; 19(7): 564–573. Published online 2017 Jun 10. doi: 10.1016/j.neo.2017.03.002
PMCID:
PMC5470553
ArticlePDF–902K
20.
The interference of Notch1 target Hes1 affects cell growth, differentiation and invasiveness of glioblastoma stem cells through modulation of multiple oncogenic targets
Carlo Cenciarelli, Hany E. Marei, Manuela Zonfrillo, Patrizia Casalbore, Armando Felsani, Stefano Giannetti, Gianluca Trevisi, Asma Althani, Annunziato Mangiola
Oncotarget. 2017 Mar 14; 8(11): 17873–17886. Published online 2017 Feb 2. doi: 10.18632/oncotarget.15013
PMCID:
PMC5392293
ArticlePDF–3.8M

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

You are here: NCBI > Literature > PubMed Central (PMC)
Support Center